About City of Hope

City of Hope is an independent biomedical research and treatment organization for cancer, diabetes, and other life-threatening diseases.

Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hope’s translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin, monoclonal antibodies and numerous breakthrough cancer drugs are based on technology developed at the institution. AccessHope™, a subsidiary launched in 2019 serves employers and their health care partners by providing access to City of Hope’s specialized cancer expertise.

A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope is ranked among the nation’s “Best Hospitals” in cancer by U.S. News & World Report and received Magnet Recognition from the American Nurses Credentialing Center. Its main campus is located near Los Angeles, with additional locations throughout Southern California and in Arizona.

City of Hope’s commitment to Diversity, Equity, and Inclusion

We believe diversity, equity and inclusion is key in serving our mission to provide compassionate patient care, drive innovative discovery, and advance vital education focused on eliminating cancer and diabetes in all our communities. Our commitment to Diversity, Equity and Inclusion ensures we bring the full range of skills, perspectives, cultural backgrounds, and experiences to our work - and that our teams align with the people we serve to build trust and understanding. We are dedicated to fostering a community that embraces diversity - in ideas, backgrounds, and perspectives; this is reflected in our work and represented in our people.

Position Summary

Dr. Danilov and Ball’s laboratory investigates epigenetic mechanisms of drug resistance in hematologic malignancies. Gene dysregulation and altered post-translational control are hallmarks of cancer.

Our research focuses on the role of epigenetic dysregulation of pro-survival pathways, and how this signaling can be targeted. In addition to a variety of in vitro models of the stromal niche, our laboratory models hematologic malignancies in vivo. Dr. Danilov’s research is highly translational and involves work with primary samples from patients with hematologic malignancies. Based on laboratory findings, Dr. Danilov's group originates early-phase clinical trials, allowing for verification of laboratory findings in the clinical setting. The lab also conducts analysis of correlative samples from patients enrolled on clinical trials.

Dr. Danilov’s laboratory receives funding from the National Cancer Institute (R01), Leukemia & Lymphoma Society, American Society of Hematology and industry partners. Dr. Ball receives funding from the National Institute of Health (K12) and industry partners.

Basic education, experience and skills required for consideration:

• Bachelors degree in life sciences or related field with 0-2 years of laboratory experience. Position is Research Associate I or Research Associate II based on education and level of experience.
• Molecular Biology experience preferred
• Ability to prioritize multiple tasks at one time
• Must have excellent communication, analytical and organizational skills: both written and verbal.
• Ability to work independently and as part of a team while being collaborative in resolving problems.
• Must be proficient with computers running Windows and PC applications (MS Excel, Oracle, Access, Word and PowerPoint).
• Must have demonstrated excellent customer service skills both on the phone and in person.
• Must possess energy and drive to coordinate multiple projects simultaneously.
• Ability to use tact and diplomacy to maintain effective working relationships

Additional Information:

As a condition of employment, City of Hope requires staff to comply with all state and federal vaccination mandates.

• For more information on Dr. Brian Ball’s research please visit here
• For more information on Dr. Alexey Danilov’s research please visit here

City of Hope is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, religion, color, national origin, sex, sexual orientation, gender identity, age, status as a protected veteran, or status as a qualified individual with disability.